Literature DB >> 27651332

GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?

Michael A Nauck1, Juris J Meier2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27651332     DOI: 10.1016/S2213-8587(16)30263-7

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN: 2213-8587            Impact factor:   32.069


× No keyword cloud information.
  6 in total

Review 1.  Renal physiology of glucose handling and therapeutic implications.

Authors:  David Z Cherney; Mehmet Kanbay; Julie A Lovshin
Journal:  Nephrol Dial Transplant       Date:  2020-01-01       Impact factor: 5.992

2.  Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses.

Authors:  Richard E Pratley; Matthew J Crowley; Mette Gislum; Christin L Hertz; Thomas B Jensen; Kamlesh Khunti; Ofri Mosenzon; John B Buse
Journal:  Diabetes Ther       Date:  2021-03-04       Impact factor: 2.945

3.  High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination.

Authors:  Marvin Wei Jie Chua
Journal:  Clin Pract       Date:  2021-12-21

4.  Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitor as an Add-on Drug to GLP-1 Receptor Agonists for Glycemic Control of a Patient with Prader-Willi Syndrome: A Case Report.

Authors:  Yukio Horikawa; Mayumi Enya; Makie Komagata; Ken-Ichi Hashimoto; Masayo Kagami; Maki Fukami; Jun Takeda
Journal:  Diabetes Ther       Date:  2018-01-15       Impact factor: 2.945

5.  Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study.

Authors:  S Ghosal; B Sinha
Journal:  Clin Diabetes Endocrinol       Date:  2018-05-09

6.  Efficacy of liraglutide added to sodium-glucose cotransporter-2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post-hoc analysis of LIRA-ADD2SGLT2i.

Authors:  Lawrence Blonde; Udi Fainberg; Margit S Kaltoft; Ofri Mosenzon; Chethana Ramesh; Rosangela Rea
Journal:  Diabetes Obes Metab       Date:  2021-07-08       Impact factor: 6.577

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.